Chronic Kidney Disease : Role of Biological Factors and Apolipoprotein L1 Encoding Gene (APOL1)

Plain-language summary

This study explores the role of biological factors and the APOL1 gene in chronic kidney disease. It included Afro-Caribbean people aged 18 and over living in Guadeloupe, either with advanced (stage 4) chronic kidney disease or with normal kidney function. It was a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Centre Hospitalier Universitaire de la Guadeloupe

Start date

4/6/2023

Estimated completion

4/6/2025

Countries

Guadeloupe

Related genes

Locations

• Pointe-à-Pitre, Guadeloupe

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients 18 y and older, of both sexes, Afro Caribbeans
* Living in Guadeloupe
* Having been informed of objectives and constraints of the study and who have given their written consent.
* For patients with CKD : at stage 4 (GFR \< than 30 ml / min / 1.73m2.), whatever the etiology of CKD, associated pathologies and treatments,
* For patients with normal renal function : serum creatinine \< 10 mg/l.

Exclusion Criteria:

* Patients 18 y and older, of both sexes, Afro Caribbeans
* Living in Guadeloupe
* Having been informed of objectives and constraints of the study and who have given their written consent.
* For patients with CKD : at stage 4 (GFR \< than 30 ml / min / 1.73m2.), whatever the etiology of CKD, associated pathologies and treatments,
* For patients with normal renal function : serum creatinine \< 10 mg/l.